With so much information being put out daily about the Covid-19 vaccine, where exactly are we in the race to deliver them worldwide?
The following is an overview of what we know about the race to deliver vaccines to help end the coronavirus pandemic, which has killed more than 1.8 million people worldwide:
WHO IS FURTHEST ALONG?
U.S. drugmaker Pfizer and German partner BioNTech have been the COVID-19 vaccine trailblazers.
On Nov. 18, they became the first in the world to release full late-stage trial data. Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada on Dec. 9 and the U.S. Food and Drug Administration (FDA) on Dec. 11. Several other countries, including Saudi Arabia and Mexico, have also approved it.
The European Medicines Agency (EMA) approved the shot on Dec. 21 and India is accelerating its review.
The World Health Organization on Thursday listed the vaccine for emergency use, in a move seeking to speed access to it in the developing world.
WHAT ABOUT MODERNA?
Moderna Inc was a close second to Pfizer in many countries after it released a full data analysis for a late-stage trial on Nov. 30 showing a 94.1% efficacy rate for its vaccine.
Moderna Inc was a close second to Pfizer in many countries after it released a full data analysis for a late-stage trial on Nov. 30 showing a 94.1% efficacy rate for its vaccine.
The United States authorised Moderna’s vaccine on Dec. 19, while Canada approved the shot on Dec. 23 and the European Medicines Agency (EMA) will do so on Jan. 6.
ASTRAZENECA
India approval of a two-dose version of AstraZeneca’s vaccine, COVISHIELD, which has also been given the green light by Britain, Argentina and El Salvador, is a major win for a shot seen as crucial for mass immunisations.
Questions about the robustness of its trial data have complicated the approval process.
The British company announced interim late-stage trial data in November showing two full doses were 62% effective while a half-dose followed by a full dose had a 90% success rate – but UK regulators the more successful outcome had not stood up to analysis.
AstraZeneca is also in discussions with the European Union’s European Medicines Agency, which is conducting a rolling review of the vaccine.
WHO ELSE IS IN THE RUNNING?
U.S. drugmaker Johnson & Johnson plans to deliver trial data in January, teeing it up for U.S. authorisation in February if its shot is effective. It reduced the enrolment target for its clinical trial to 40,000 volunteers from 60,000 on Dec. 9, potentially speeding results that are tied to how quickly participants become infected.
U.S. firm Novavax is running a late-stage trial in Britain with data due in the first quarter of 2021. It expects to start a large-scale trial in the United States this month.
France’s Sanofi and Britain’s GlaxoSmithKline , however, announced a setback on Dec. 11 in their attempts to develop a vaccine. The drugmakers said that it showed an insufficient immune response in older people in mid-stage trials and that they would start a new study in February.
WHAT HAPPENS IN THE TRIALS?
The companies usually test their vaccines against a placebo – typically saline solution – in healthy volunteers to see whether the rate of COVID-19 infection among those who got the vaccine is significantly lower than in those who received the dummy shot.
HOW ARE VOLUNTEERS INFECTED?
The trials rely on subjects becoming naturally infected with COVID-19, so how long it takes to generate results largely depends on how pervasive the virus is where trials are being conducted. Each drugmaker has targeted a specific number of infections to trigger a first analysis of their data.
HOW WELL ARE THE VACCINES SUPPOSED TO WORK?
The World Health Organization ideally wants to see at least 70% efficacy. The FDA wants at least 50% – which means there must be at least twice as many infections among volunteers who received a placebo as among those in the vaccine group. The EMA has said it may accept a lower efficacy level.
WHAT ABOUT RUSSIA AND CHINA?
Although Pfizer’s shot was the first to be rolled out following the publication of full Phase III trial data, Russia and China have been inoculating their citizens for months with several different vaccines still undergoing late-stage trials.
China on Dec. 31. approved its first COVID-19 vaccine for general public use, a shot developed by an affiliate of state-backed pharmaceutical giant Sinopharm. The company said it is 79% effective against the virus.
Russia said on Nov. 24 its Sputnik V vaccine, developed by the Gamaleya Institute, was 91.4% effective based on interim late-stage trial results. It started vaccinations in August and has inoculated more than 100,000 people so far.
India plans to make 300 million doses of Sputnik V next year and Argentina has given the green light for emergency use of the shot, with some 300,000 doses arriving in the country on Dec. 24.
China launched an emergency use programme in July aimed at essential workers and others at high risk of infection. It has vaccinated about one million people as of mid-November using at least three shots – 1 developed by the state-backed China National Biotec Group (CNBG) and one by Sinovac Biotech.
Trial data on a COVID-19 vaccine developed by China’s Sinovac Biotech has varied: interim data from a late-stage trial in Turkey showed its CoronaVac shot is 91.25% effective, while researchers in Brazil say the shot was more than 50% effective.
ASTRAZENECA
India approval of a two-dose version of AstraZeneca’s vaccine, COVISHIELD, which has also been given the green light by Britain, Argentina and El Salvador, is a major win for a shot seen as crucial for mass immunisations.
Questions about the robustness of its trial data have complicated the approval process.
The British company announced interim late-stage trial data in November showing two full doses were 62% effective while a half-dose followed by a full dose had a 90% success rate – but UK regulators the more successful outcome had not stood up to analysis.
AstraZeneca is also in discussions with the European Union’s European Medicines Agency, which is conducting a rolling review of the vaccine.
WHO ELSE IS IN THE RUNNING?
U.S. drugmaker Johnson & Johnson plans to deliver trial data in January, teeing it up for U.S. authorisation in February if its shot is effective. It reduced the enrolment target for its clinical trial to 40,000 volunteers from 60,000 on Dec. 9, potentially speeding results that are tied to how quickly participants become infected.
U.S. firm Novavax is running a late-stage trial in Britain with data due in the first quarter of 2021. It expects to start a large-scale trial in the United States this month.
France’s Sanofi and Britain’s GlaxoSmithKline , however, announced a setback on Dec. 11 in their attempts to develop a vaccine. The drugmakers said that it showed an insufficient immune response in older people in mid-stage trials and that they would start a new study in February.
WHAT HAPPENS IN THE TRIALS?
The companies usually test their vaccines against a placebo – typically saline solution – in healthy volunteers to see whether the rate of COVID-19 infection among those who got the vaccine is significantly lower than in those who received the dummy shot.
HOW ARE VOLUNTEERS INFECTED?
The trials rely on subjects becoming naturally infected with COVID-19, so how long it takes to generate results largely depends on how pervasive the virus is where trials are being conducted. Each drugmaker has targeted a specific number of infections to trigger a first analysis of their data.
HOW WELL ARE THE VACCINES SUPPOSED TO WORK?
The World Health Organization ideally wants to see at least 70% efficacy. The FDA wants at least 50% – which means there must be at least twice as many infections among volunteers who received a placebo as among those in the vaccine group. The EMA has said it may accept a lower efficacy level.
WHAT ABOUT RUSSIA AND CHINA?
Although Pfizer’s shot was the first to be rolled out following the publication of full Phase III trial data, Russia and China have been inoculating their citizens for months with several different vaccines still undergoing late-stage trials.
China on Dec. 31. approved its first COVID-19 vaccine for general public use, a shot developed by an affiliate of state-backed pharmaceutical giant Sinopharm. The company said it is 79% effective against the virus.
Russia said on Nov. 24 its Sputnik V vaccine, developed by the Gamaleya Institute, was 91.4% effective based on interim late-stage trial results. It started vaccinations in August and has inoculated more than 100,000 people so far.
India plans to make 300 million doses of Sputnik V next year and Argentina has given the green light for emergency use of the shot, with some 300,000 doses arriving in the country on Dec. 24.
China launched an emergency use programme in July aimed at essential workers and others at high risk of infection. It has vaccinated about one million people as of mid-November using at least three shots – 1 developed by the state-backed China National Biotec Group (CNBG) and one by Sinovac Biotech.
Trial data on a COVID-19 vaccine developed by China’s Sinovac Biotech has varied: interim data from a late-stage trial in Turkey showed its CoronaVac shot is 91.25% effective, while researchers in Brazil say the shot was more than 50% effective.
The United Arab Emirates, meanwhile, said on Dec. 9 that one of the CNBG vaccines was 86% effective based on interim results from a late-stage trial in the Gulf Arab state.
Sourced Reuters
Editing by Caroline Humer, David Clarke, Mark Potter, Josephine Mason, Louise Heavens and Gerry Doyle
For more Finance and Investment news follow i-invest Online.
- How digital vaults can future-proof enterprises for the AI era
As AI accelerates demand for high-quality, large-scale data, Alex Segeda of Western Digital explores whether enterprises can afford not to preserve their archives strategically AI has created unprecedented demand on enterprise data, and this information surge has exposed one uncomfortable truth: many organisations sit on huge data reserves they cannot meaningfully leverage. The rush to… Read more: How digital vaults can future-proof enterprises for the AI era - Chainguard Catalog Starter: Build with open source software you can trust
The industry’s largest catalogue of trusted container images now offers free, production-ready images to accelerate secure software development Chainguard, the trusted source for open source, has announced Chainguard Catalog Starter, providing developers with free access to a starter pack of Chainguard base, application, and AI images of their choice from the industry’s most comprehensive container image… Read more: Chainguard Catalog Starter: Build with open source software you can trust - Supply chain risk starts where transparency ends
It’s time for businesses to recognise that scientific integrity is critical to ethical supply management, says Rupert Hodges of origin verification pioneers Oritain Today, the global supply chain is at an inflection point, driven by geopolitical volatility and the climate crisis. This change requires a shift away from networks optimised solely for cost, instead moving… Read more: Supply chain risk starts where transparency ends - Learn the hidden behaviours of history’s great strategists
History’s great strategic thinkers prove that strategy isn’t about theory, it’s about behaviour, and impact follows those who practise a certain approach, writes Charlie Curson Senior leaders often assume strategy is about intellect, information, or industry expertise. But history’s greatest strategists – across fields as diverse as civil rights, science, sport, politics, exploration and business… Read more: Learn the hidden behaviours of history’s great strategists - Chainguard achieves 94% Python coverage across customer environments
Chainguard expands coverage and impact across Python, Java, and JavaScript libraries, securing the open source dependencies engineering teams rely on Chainguard, the trusted source for open source, recently announced it has expanded Chainguard Libraries coverage across Python, Java, and JavaScript, with customers seeing 94% coverage across the Python dependencies they use in their environments. Given Chainguard Libraries are… Read more: Chainguard achieves 94% Python coverage across customer environments